Sutro Biopharma (STRO) Expected to Announce Earnings on Monday

Sutro Biopharma (NASDAQ:STRO) is projected to release its earnings data before the market opens on Monday, March 24th. Analysts expect Sutro Biopharma to post earnings of ($0.86) per share and revenue of $12.18 million for the quarter.

Sutro Biopharma (NASDAQ:STRO) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($2.96) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($2.10). The company had revenue of $14.00 million during the quarter, compared to analyst estimates of $10.44 million. Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. During the same period in the previous year, the company posted ($1.78) EPS. On average, analysts expect Sutro Biopharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Sutro Biopharma Trading Down 3.7 %

Shares of STRO stock opened at $0.77 on Friday. The stock has a market cap of $63.24 million, a price-to-earnings ratio of -0.48 and a beta of 1.22. The stock has a 50-day moving average of $1.64 and a 200-day moving average of $2.61. Sutro Biopharma has a 1-year low of $0.76 and a 1-year high of $6.13.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Piper Sandler set a $2.00 price target on Sutro Biopharma in a research note on Friday, March 14th. JMP Securities reissued a “market outperform” rating and issued a $17.00 price target on shares of Sutro Biopharma in a research note on Wednesday, December 11th. Bank of America cut Sutro Biopharma from a “buy” rating to an “underperform” rating and decreased their price target for the company from $11.00 to $1.00 in a research note on Friday, March 14th. Citizens Jmp lowered Sutro Biopharma from an “outperform” rating to a “market perform” rating in a research report on Friday, March 14th. Finally, Wedbush lowered Sutro Biopharma from an “outperform” rating to a “neutral” rating and cut their target price for the company from $8.00 to $2.00 in a research report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $6.63.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.